PROMENADE: PembROlizuMab for early triple negative ER-Low Breast Cancer, real world french cohort.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Impactful Shortlisted Abstracts/Publications in TNBC
Chairpersons :
Dr. S. S. Nirni, Dr. Boman Dhabhar
Speaker :
Dr. Devavrat Arya